A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

NCT06394167 | Completed Phase 1 FDA Drug

• 1 other identifier: VX23-993-002
• Study Type: interventional
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of intravenously administered VX-993 at different doses in healthy participants.

Conditions

Pain

Outcome Measures

Primary Outcomes (2)

• Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

  Day 1 up to Day 16

• Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

  Day 1 up to Day 43

Secondary Outcomes (4)

• Part A: Maximum Observed Plasma Concentration (Cmax) of VX-993

  Pre-dose up to Day 16

• Part B: Maximum Observed Plasma Concentration (Cmax) of VX-993

  Pre-dose up to Day 43

• Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-993

  Pre-dose up to Day 16

• Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-993

  Pre-dose up to Day 43

Study Arms (4)

Part A: Single Ascending Dose (SAD)

EXPERIMENTAL

Participants will be randomized to receive a single dose of different dose levels of VX-993.

Drug: VX-993

Part B: Multiple Ascending Dose (MAD)

EXPERIMENTAL

Participants will be randomized to receive multiple doses of different dose levels of VX-993. The dose levels will be determined based on the data from Part A.

Drug: VX-993

Placebo Part A

PLACEBO COMPARATOR

Participants will be randomized to receive placebo matched to VX-993.

Drug: Placebo

Placebo Part B

PLACEBO COMPARATOR

Participants will be randomized to receive multiple doses of placebo matched to VX-993.

Drug: Placebo

Interventions

VX-993 DRUG

Solution for IV administration.

Part A: Single Ascending Dose (SAD); Part B: Multiple Ascending Dose (MAD)

Placebo DRUG

Solution for IV administration.

Placebo Part A; Placebo Part B

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
• A total body weight of more than (\>) 50 kg
• Nonsmoker or ex-smoker for at least 3 months before first dose of the study drug

You may not qualify if:

• History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug.
• Any condition possibly affecting drug distribution, metabolism, or excretion

Sponsors & Collaborators

• Vertex Pharmaceuticals Incorporated: lead

Study Sites (1)

ICON Lenexa

Lenexa, Kansas, 66219, United States

Location

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 26, 2024
• First Posted: May 1, 2024
• Study Start: May 9, 2024
• Primary Completion: February 18, 2025
• Study Completion: February 18, 2025
• Last Updated: March 20, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)